Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories

Executive Summary

In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.

Advertisement

Related Content

Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure
Califf's Priorities Feature Short- And Long-Term Goals Despite Potentially Brief Tenure
Blame The Science, Not Regulation, For Targeted Therapy Shortfalls – FDA
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
FDA Flexible With Accelerated Approval Evidence, Analysis Finds
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
FDA's Spielberg To Focus On Cross-Center Collaboration, Hamburg Says

Topics

Advertisement
UsernamePublicRestriction

Register